Latest Daily News

More Stories

June 3, 2017

TRK is uncommonly expressed in normal tissues and in most cancers, and TRK fusions are found in a diverse range of cancer types.

Read more
May 25, 2017

The explosion of precision medicine and genomics research over the last decade or more has revolutionized the field of oncology. Two Education Sessions will offer updates on genomics research along with practical advice about how to incorporate precision medicine techniques into practice.

Read more
May 25, 2017

Dr. Eric Kmiec summarizes advances in real-time gene editing and cancer immunotherapy. Such advances, including CTLA-4 and PD-1 blockade, as well as CRISPR/Cas9 and CAR-based manipulations, are being explored in multiple ongoing clinical trials worldwide.

Read more

May 25, 2017

Authors discuss the most up-to-date research on using chemotherapy treatments for good-risk germ cell tumors, focusing on the use of post-chemotherapy retroperitoneal lymph node dissection and the need for continued, longer-term studies.

Read more

May 25, 2017

SIOPEN results presented at the 2011 ASCO Plenary Session changed the standard of care for high-risk neuroblastoma in Europe but not in North America. Standard of care in North America now is tandem autologous stem cell transplants.

Read more
June 6, 2016

A proprietary plasma DNA genomic sequencing platform demonstrated high sensitivity and positive predictive value and detected mutation sequences that confer resistance to therapy.

Read more

June 7, 2016

CALGB/SWOG 80405 as well as a large population-based study report on clinical outcomes in patients with advanced colorectal cancers based on the location of the primary tumor. Do left-sided tumors fare better than right-sided tumors and what are the implications for clinical practice?

Read more

May 26, 2016

The discovery of postnatal activation of the fundamental developmental Hedgehog (Hh) signaling pathway has opened a new field for pharmaceutical intervention and modulation. Several Hh pathway antagonists have been evaluated in phase I and II trials, and at least two have been approved for use.

Read more

May 26, 2016

Drs. Jeremy Jones and Axel Grothey explore the challenges of and research into the treatment of colorectal cancer in the presence of BRAF mutations.

Read more

May 26, 2016

Dr. Robert Kerbel explains evolving roles of VEGF pathway–targeting drugs and explores the potential mechanisms and uses in combination therapies.

Read more
May 26, 2016

The B-cell receptor pathway has recently become a target for treatment of many incurable B-cell malignancies, including mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic leukemia, and chronic lymphocytic leukemia. 

Read more

May 26, 2016

The EGFR signaling pathway is one of the most important for regulation of growth, proliferation, and differentiation in mammalian cells. Overexpression of EGFR and its ligands has been demonstrated in many types of tumors such as lung and breast cancers, CRCs, HNSCC, and glioblastoma.

Read more

May 26, 2016

Dr. William G. Kaelin is honored with the 2016 Science of Oncology Award and Lecture for providing new insights into the biochemical functions of tumor suppressor proteins and their role in cancer development.

Read more
May 26, 2016

ASCO released a new policy statement with recommendations to ensure that clinical pathways in oncology promote—and do not hinder—the care of patients with cancer. 

Read more

May 21, 2015

In this article from 2013, Dr. Daniel Cho provides an in-depth look into the PI3K pathway.

Read more
May 30, 2015

Data presented at a clinical science symposium stated that nivolumab may be a promising treatment for patients with advanced hepatocellular carcinoma, while patients with tumors having genetic defects in mismatch repair respond significantly better to therapy with the PD-1 inhibitor pembrolizumab.

Read more
May 30, 2015

Data from CheckMate 057 indicated that patients with refractory, advanced nonsquamous NSCLC who received nivolumab monotherapy demonstrated significantly superior overall survival versus docetaxel.

Read more
June 1, 2015

Continuing bevacizumab beyond progression confers no apparent clinical benefit in recurrent glioblastoma patients compared with cessation of the drug, according to results of the second part of a randomized trial. Neither progress-free survival nor OS was any different with continuing bevacizumab.

Read more
June 10, 2015

The addition of the tumor treating fields device to adjuvant temozolomide for patients with glioblastoma demonstrated an improvement in progression-free survival and overall survival.

Read more
May 31, 2015

Significant strides have been made in immunomodulatory approaches to treating patients with either primary or recurring glioblastoma. Researchers at the ASCO Annual Meeting discussed three distinct approaches being investigated for this indication.

Read more